SCHEMBL5778170

SCHEMBL5778170

CC(=O)Oc1ccccc1-c1nc2cc(F)ccc2c(=O)o1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.64
ELANE P08246 1/20 0.58
C1R P00736 4/20 0.55
APEX1 P27695 1/20 0.52
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
CTSG P08311 5/20 0.50
KLK7 P49862 5/20 0.50
KLK14 Q9P0G3 5/20 0.50
KLK5 Q9Y337 5/20 0.50
PRSS1 P07477 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CTRC Q99895 1/20 0.46
NPC1 O15118 1/20 0.46
HSP90AA1 P07900 1/20 0.46
RAB9A P51151 1/20 0.46
CD74 P04233 1/20 0.45
MIF P14174 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5921548 0.91 C1R (0.55) PKMELANEC1RALDH1A1LMNA
SCHEMBL5779985 0.87 ELANE (0.77) PKMELANEC1RAPEX1ALDH1A1
SCHEMBL5778141 0.86 C1R (0.73) PKMELANEC1RALDH1A1LMNA
SCHEMBL5921076 0.81 C1R (0.65) PKMELANEC1RALDH1A1LMNA
SCHEMBL5781524 0.81 C1R (0.55) PKMELANEC1RALDH1A1LMNA
SCHEMBL17254720 0.81 CD74 (0.67) PKMELANEC1RALDH1A1LMNA
SCHEMBL17554083 0.81 APEX1 (0.76) ELANEC1RAPEX1MAPTPRSS1
SCHEMBL5921767 0.80 C1R (0.63) PKMELANEC1RAPEX1ALDH1A1
SCHEMBL5777065 0.80 MAOB (0.49) PKMELANEC1RALDH1A1LMNA
SCHEMBL5921134 0.79 C1R (0.68) PKMELANEC1RALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558260-A4 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMA INC (US) 2006-10-25 EP disclosed
US-20060052345-A1 Quinazolinone compounds as calcilytics NPS PHARMACEUTICALS, INC. (US) 2006-03-09 US disclosed
CN-1708306-A Quinazolinone compounds as calcilytics NPS PHARMA INC (US) 2005-12-14 CN disclosed
EP-1558260-A2 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2005-08-03 EP disclosed
WO-2004041755-A2 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052345-A1 Quinazolinone compounds as calcilytics CALCR, CALCRL, CASR PKM 4408/4885ELANE 3009/4885C1R 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.